Advertisement

Picture [iito] Back into Ad 650x80px
Employment/Membership › Details

Qlife–Rousøe KD: management, 202203– CFO before Phase One A/S + Bauer Media Group + Mono Solutions + Designit A/S

 

Period Period 2022-03-01
Organisations Organisation Qlife Holding AB
  Organisation 2 OTHER
Product Product MedTech (medical technology)
Person Person Rousøe, Kasper Damgaard (Qlife 202203– CFO before Phase One A/S + Bauer Media Group + Mono Solutions + Designit A/S)
     

Qlife Holding AB. (11/29/21). "Press Release: Qlife Recruits Kasper Damgaard Rousøe as New Chief Financial Officer".

Qlife has recruited Kasper Damgaard Rousøe as new Chief Financial Officer (CFO) for Qlife Holding AB and subsidiary Qlife Aps. Kasper comes most recently from Phase One A/S and will begin his new role no later than 1 March 2022. Current CFO in Qlife Aps Lars Bangsgaard has decided to retire from his position, and part-time CFO in Qlife Holding AB Henrik Ljung will end his assignment at the end of Q1 2022.

Kasper Rousøe has more than 20 years of experience from leading roles in the financial area, most recently from Phase One A/S. He has previously been CFO and Finance Director in Bauer Media Group, Mono Solutions and Designit A/S, and has through his roles gained international experience
from the software, hardware, and creative industries. Kasper hold a M. Sc. in Economics from Copenhagen University and an EMBA from Lausanne in Switzerland.

"I am very happy to welcome Kasper to Qlife. In addition to solid expertise in finance, he has broad knowledge of manufacturing, procurement and IT products and processes. Qlife is in a very expansive phase, and Kasper will be an important part of the company's group management and I look forward to working with him" says Qlife’s CEO Thomas Warthoe.

"It feels incredibly exciting to be a part of Qlife and it’s mission to revolutionize the market for clinical biomarker and virus tests with it’s game-changing potential. I look forward to working with Qlife’s team in realising the commercial potential and growth opportunities" says Kasper
Rousøe.

Lars Bangsgaard is part of the original founder’s group and will remain a major share owner in Qlife (7.8%).


For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34


Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

   
Record changed: 2022-05-23

Advertisement

Picture [iito] Männer Ballett 650x100px

More documents for Qlife Holding AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px




» top